Robert G Lambert Selected Research

Ankylosing Spondylitis

1/2018	Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
1/2013	Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification.
5/2002	Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert G Lambert Research Topics

Disease

9	Axial Spondyloarthritis 02/2024 - 04/2014
6	Inflammation (Inflammations) 05/2024 - 01/2013
4	Non-Radiographic Axial Spondyloarthritis 09/2022 - 01/2018
3	Sacroiliitis 09/2022 - 01/2019
3	Ankylosing Spondylitis 01/2018 - 05/2002
3	Necrosis 01/2018 - 01/2013
2	Ankylosis 04/2014 - 01/2013
1	Spondylarthropathies 05/2024
1	Psoriatic Arthritis 01/2021
1	Rheumatoid Arthritis 01/2020
1	Nasopharyngitis 01/2018
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2018
1	Metaplasia 04/2014
1	Infections 05/2002
1	Joint Diseases (Joint Disease) 05/2002

Drug/Important Bio-Agent (IBA)

4	Etanercept (Enbrel)FDA Link 02/2024 - 01/2018
4	Adalimumab (Humira)FDA Link 01/2018 - 01/2013
2	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 04/2014
2	FluoridesIBA 01/2019 - 01/2019
1	ixekizumabIBA 09/2022
1	C-Reactive ProteinIBA 09/2022
1	Interleukin-17 (Interleukin 17)IBA 09/2022
1	Antirheumatic Agents (DMARD)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Fenofibrate (CiL)FDA LinkGeneric 01/2013
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2002
1	Neutralizing AntibodiesIBA 05/2002
1	Infliximab (Remicade)FDA Link 05/2002
1	GadoliniumIBA 05/2002

Therapy/Procedure

7	Therapeutics 01/2018 - 05/2002